hexane-1,6-diyl dihexadecanoate | 23130-50-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: hexane-1,6-diyl dihexadecanoate
• 英文别名: 1,6-hexanediol dipalmitate；1,6-Dipalmitoyloxy-hexan；Hexamethylenglycoldipalmitat；Hexamethylenglykol-dipalmitat；1,6-dihydroxy-hexane-bis-palmitoyl ester；1,6-bis-palmitoyloxy-hexane；1,6-Bis-palmitoyloxy-hexan；hexamethylene palmitate；6-hexadecanoyloxyhexyl hexadecanoate
• CAS: 23130-50-9
• 化学式: C₃₈H₇₄O₄
• 分子量: 595.003
• InChiKey: IBYKYYZAEVHVLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.1
• 重原子数：
  42
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,6-己二醇 、 棕榈酸 在 对甲苯磺酸 作用下， 生成 hexane-1,6-diyl dihexadecanoate
  参考文献：
  名称：

  Naudet,M.; Derbesy,M., Bulletin de la Societe Chimique de France, 1963, p. 173

  摘要：

  DOI：

文献信息

• Use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered, and device for transdermal delivery
  申请人：Alko Ltd.

  公开号：EP0429039A2

  公开（公告）日：1991-05-29

  The use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered simultaneously or separately sequentially with alcohol and a device for transdermally administering the antagonist. The device is a package containing a fixed dose of opiate antagonist, a vehicle and a permeation enhancer.

  使用鸦片拮抗剂制备一种药物组合物，与酒精同时或分别顺序透皮给药，以及一种透皮给药拮抗剂的装置。该装置是一个包装，内含固定剂量的阿片类拮抗剂、载体和渗透促进剂。
• A transdermal delivery system for treatment of cocaine and heroin addiction
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0432945A1

  公开（公告）日：1991-06-19

  For the treatment of cocaine and heroin addiction in a human or animal subject, there is disclosed a transdermal delivery system which includes as the active ingredient buprenorphine or a pharmaceutically-acceptable salt.

  为治疗人或动物的可卡因和海洛因成瘾，公开了一种透皮给药系统，其活性成分包括丁丙诺啡或药学上可接受的盐。
• Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP1595542A1

  公开（公告）日：2005-11-16

  The present invention is related to the use of a compound of the general formula wherein R is methyl, ethyl, ethyl substituted with one or more fluorine atoms, or cycloalkyl-(C3-C7)-methyl optionally substituted with one or more fluorine atoms or benzyl optionally substituted with a group selected from phenyl, furanyl and thienyl which groups are optionally substituted with 1-3 substituents from the group hydroxy, halogen, C1-4-alkoxy, C1-4-alkyl, cyano, aminocarbonyl, mono- or di-C1-4-alkylaminocarbonyl; and pharmaceutically acceptable salts and prodrugs thereof, for the manufacture of a composition for transdermal administration by iontophoresis.

  本发明涉及通式如下的化合物的用途 其中 R 是甲基、乙基、被一个或多个氟原子取代的乙基或任选被一个或多个氟原子取代的环烷基-(C3-C7)-甲基或任选被选自苯基、呋喃基和噻吩基的基团取代的苄基，这些基团任选被羟基、卤素、C1-4-烷氧基、C1-4-烷基、氰基、氨基羰基、单-或双-C1-4-烷基氨基羰基中的 1-3 个取代基取代；及其药学上可接受的盐和原药，用于制造通过离子透入法进行透皮给药的组合物。
• Use of naloxone for treating eating disorders
  申请人：Sinclair, John D.

  公开号：EP1681057A1

  公开（公告）日：2006-07-19

  Use of naloxone for the preparation of a pharmaceutical composition for treating eating disorders by a method based on selective extinction. In such a method a pharmaceutical composition is administered simultaneously with the patient making eating disorder responses but in a manner so that effective levels of naloxone are not present in the body when the patient makes healthy eating responses, and continuing the alternating between extinction of eating disorder responses with naloxone and reinforcement of healthy eating behaviors until the eating disorder responses are weak enough to be controlled. By means of the invention, eating disorders, such as binge eating, bulimia, bulimia-like syndrome, anorexia nervosa, and habitual over-eating stimulated by specific stimuli including certain foods, situations, or moods, can be efficiently treated.

  使用纳洛酮制备药物组合物，通过基于选择性灭绝的方法治疗进食障碍。在这种方法中，在患者做出进食障碍反应的同时给药药物组合物，但给药方式应使患者做出健康饮食反应时体内不存在有效水平的纳洛酮，并继续交替使用纳洛酮熄灭进食障碍反应和强化健康饮食行为，直到进食障碍反应弱到足以被控制为止。通过本发明，可以有效治疗饮食失调症，如暴饮暴食、贪食症、贪食症样综合征、神经性厌食症，以及由特定刺激（包括某些食物、情况或情绪）引起的习惯性过度进食。
• Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
  申请人：EMORY UNIVERSITY

  公开号：US10376524B2

  公开（公告）日：2019-08-13

  GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.

  GABAA受体介导的嗜睡症可以通过施用GABAA受体拮抗剂（如氟马西尼、克拉霉素、苦参碱、双桉碱、西曲霉毒素和烯诺毒素）来治疗。在某些实施方案中，GABAA 受体拮抗剂是氟马西尼或克拉霉素。GABAA 受体介导的嗜睡症包括轮班工作睡眠障碍、阻塞性睡眠呼吸暂停/呼吸暂停综合征、嗜睡症、过度嗜睡、嗜睡症（如GABAA受体介导的嗜睡症包括轮班工作睡眠障碍、阻塞性睡眠呼吸暂停/呼吸暂停综合征、过度嗜睡、嗜睡症（如特发性嗜睡症、复发性嗜睡症、与内氮平类药物相关的复发性昏睡和苯丙胺抵抗性嗜睡症），以及与轮班工作睡眠障碍、阻塞性睡眠呼吸暂停/呼吸暂停综合征和嗜睡症（如特发性嗜睡症、复发性嗜睡症、与内氮平类药物相关的复发性昏睡和苯丙胺抵抗性嗜睡症）相关的过度嗜睡。